Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 144Sarcoma 19Tumor-Agnostic 11Genitourinary 11Gynecologic 8Thoracic 7Other solid neoplasm 6CNS 5Gastrointestinal 4Lymphoid 2Head & Neck 2Dermatologic 2

Conditions

Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Head and Neck Neoplasms 1

Interventions

Cisplatin 619pembrolizumab 323Radiotherapy 319Cetuximab 274Docetaxel 220Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 74Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 48Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 43tislelizumab 42Standard of Care 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × eribulin × Head & Neck × Clear all
NCT01613768 2018-09-28

Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

University of Washington

Phase 2 Completed
29 enrolled 12 charts
Head & Neck

Salivary Gland Neoplasms

NCT00337129 2015-08-25

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 8 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡